Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 6/20 | 0.42 |
| ▸ | CDK8 | P49336 | 7/20 | 0.39 |
| ▸ | CCNC | P24863 | 6/20 | 0.39 |
| ▸ | POLQ | O75417 | 1/20 | 0.38 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.36 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 2/20 | 0.36 |
| ▸ | MAOB | P27338 | 2/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | USP7 | Q93009 | 1/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.35 |
| ▸ | STK16 | O75716 | 1/20 | 0.34 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1017267 | 0.91 | AR (0.45) | ARCDK8CCNCSLC16A3SLC16A1 | |
| SCHEMBL1014251 | 0.83 | CDK8 (0.43) | ARCDK8CCNCPOLQSLC16A3 | |
| SCHEMBL1013864 | 0.83 | CCNC (0.38) | ARCDK8CCNCPOLQSLC16A3 | |
| SCHEMBL14313623 | 0.81 | AR (0.46) | ARCDK8CCNCPOLQUSP7 | |
| SCHEMBL1013404 | 0.79 | AR (0.42) | ARCDK8CCNCPOLQUSP7 | |
| SCHEMBL1016472 | 0.77 | CCNC (0.45) | ARCDK8CCNCPOLQUSP7 | |
| SCHEMBL1012795 | 0.75 | CCNC (0.44) | ARCDK8CCNCPOLQMAOB | |
| SCHEMBL1013067 | 0.75 | CCNC (0.44) | ARCDK8CCNCPOLQUSP7 | |
| SCHEMBL1012899 | 0.75 | CCNC (0.44) | ARCDK8CCNCPOLQUSP7 | |
| SCHEMBL1011231 | 0.74 | CCNC (0.40) | ARCDK8CCNCPOLQUSP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8772327-B2 | Phenylpropionic acid derivative and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2014-07-08 | — | — | US | disclosed |
| US-20130131134-A1 | PHENYLPROPIONIC ACID DERIVATIVE AND USE THEREOF | MORITA KOHEI (JP) | 2013-05-23 | — | — | US | disclosed |
| US-8334314-B2 | Phenylpropionic acid derivative and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-12-18 | — | — | US | disclosed |
| EP-2272832-A1 | PHENYLPROPIONIC ACID DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2011-01-12 | — | — | EP | disclosed |
| US-20100093819-A1 | PHENYLPROPIONIC ACID DERIVATIVE AND USE THEREOF | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131134-A1 | PHENYLPROPIONIC ACID DERIVATIVE AND USE THEREOF | PLA2G12A, PLA2G4A, PLA2G4B | AR 4054/4885CDK8 4422/4885CCNC 4730/4885 |
| US-20100093819-A1 | PHENYLPROPIONIC ACID DERIVATIVE AND USE THEREOF | PLA2G12A, PLA2G4A, PLA2G4B | AR 4054/4885CDK8 4422/4885CCNC 4730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.